High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients |
| |
| Authors: | C H W Koks H Rosing P L Meenhorst A Bult J H Beijnen |
| |
| Institution: | 1. Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA;2. Department of Pharmacy, Riley Hospital for Children, Indianapolis, IN, USA;3. Department of Pediatrics, Division of Infectious Diseases, Columbia University Medical Center and New York-Presbyterian Morgan Stanley Children''s Hospital, New York, NY, USA;4. Department of Pharmacy, St. Christopher''s Hospital for Children, Philadelphia, PA, USA;5. Pediatric Pulmonology, Connecticut Children''s Medical Center, Hartford, CT, USA;6. Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC, USA;7. Department of Pharmacy, Nationwide Children''s Hospital, Columbus, OH, USA;8. Department of Pharmacy, Children''s Medical Center, Dallas, TX, USA;1. Department of Infectious Diseases, Iuliu Ha?ieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania;2. Clinical Hospital of Infectious Diseases, Cluj-Napoca, Romania;3. Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania;4. Department of Anesthesia and Intensive Care, Iuliu Ha?ieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania;5. and Department of Urology, Iuliu Ha?ieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania;2. Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL;3. Division of Cardiovascular disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL;4. Division of Pediatric Cardiac Anesthesia, Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL |
| |
| Abstract: | A high-performance liquid chromatographic (HPLC) assay has been developed for the determination of the antifungal drug fluconazole in saliva and plasma of patients infected with the human immunodeficiency virus (HIV). Samples can be heated at 60°C for 30 min to inactivate the virus without loss of the analyte. The sample pretreatment involves a liquid-liquid extraction with chloroform-1-propanol (4:1, v/v). The chromatographic analysis is performed on a Lichrosorb RP-18 (5 μm) column by isocratic elution with a mobile phase of 0.01 M acetate buffer (pH 5.0)-methanol (70:30, v/v) and ultraviolet (UV) detection at 261 nm. The lower limit of is 100 ng/ml in plasma (using 500-μl samples) and 1 μg/ml in saliva (using 250-μl samples) and the method is linear up to 100 μg/ml in plasma and saliva. At a concentration of 5 μg/ml the within-day and between-day precision in plasma are 7.1 and 5.7%, respectively. In saliva the within-day and between-day precision is 10.8% (at 5 μg/ml). The methodology is now being used in pharmacokinetic studies in HIV-infected patients in our hospital. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
